BCL2 and neoplasm: The co-delivery of both compounds was found to be more effective at treating metastatic breast cancer compared to miRNA-34a or docetaxel alone, where it reduced the expression of Bcl-2, the anti-apoptosis gene, effectively prevented tumor cell migration, and promoted cell apoptosis and cytotoxicity [190].